AID Group exited its position in Nanyang Biologics (NYB) in October 2025, redeeming an approximately 15% holding ahead of NYB's announced business combination with RF Acquisition Corp II (NASDAQ: RFAI). The combined entity, valued at approximately US$1.5 billion, is expected to list on Nasdaq in the first or second quarter of 2026.
AID first invested in NYB during the platform's early Singapore phase. NYB's flagship product, Vecura™, applies proprietary computational biology to natural compound libraries to compress the early-stage drug discovery cycle — outperforming nine leading public AI drug discovery models by an average of 27% in 2025 benchmarking and winning first prize at SuperAI Genesis 2025 across more than 700 global startups.
The decision to exit ahead of the public listing was a portfolio call. "Nanyang has earned its way to the public markets, and a SPAC combination is the right next chapter for them," Kelvin Wu wrote in an internal note. "Our capital is better deployed where we can operate — Project HBOC in Niseko, AID Genomics in Israel, and Thai Omics in Chonburi."
AID's precision-medicine pillar continues to anchor on the assets it controls and operates: AID Genomics (Israel), Thai Omics (Thailand), and Project HBOC (Niseko longevity centre). The NYB exit returned a meaningful multiple on AID's invested capital and closes one of the group's longest-held public-markets positions.
AI.D Group · Singapore / New York